Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCGP 39551
Description: Potent, selective and competitive NMDA antagonist
Chemical Name: (E)-(±)-2-Amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester
Purity: ≥98% (HPLC)
Biological Activity for CGP 39551
CGP 39551 is a potent, selective and competitive NMDA antagonist (Ki = 310 nM for inhibition of [3H]-CPP binding in rat brain). Centrally active upon oral administration in vivo.
Technical Data for CGP 39551
| M. Wt | 237.19 |
| Formula | C8H16NO5P |
| Storage | Desiccate at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 127910-32-1 |
| PubChem ID | 6372334 |
| InChI Key | OKDOWCKDTWNRCB-GQCTYLIASA-N |
| Smiles | NC(C(OCC)=O)/C=C(C)/CP(O)(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for CGP 39551
References for CGP 39551
References are publications that support the biological activity of the product.
D'Hooge et al (1999) Effects of competitive NMDA receptor antagonists on excitatory amino-acid-evoked currents in mouse spinal cord. Fundam.Clin.Pharmacol. 13 67 PMID: 10027090
Fagg et al (1990) CGP 37849 and CGP 39551: novel and potent competitive N-MthD.-asparate receptor antagonists with oral activity. Br.J.Pharmacol. 99 791 PMID: 1972895
Loscher and Honack (1991) Anticonvulsant and behavioural effects of two novel competitive N-MthD.-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamaz. J.Pharmacol.Exp.Ther. 256 432 PMID: 1671593
View Related Products by Target
View Related Products by Product Action
Keywords: CGP 39551, CGP 39551 supplier, Potent, selective, competitive, NMDA, antagonist, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, CGP39551, 1409, Tocris Bioscience
2 Citations for CGP 39551
Citations are publications that use Tocris products. Selected citations for CGP 39551 include:
Grieder et al (2012) Phasic D1 and tonic D2 DA receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. Proc Natl Acad Sci U S A 109 3101 PMID: 22308372
Bäckström and Hyytiä (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31 778 PMID: 16123768
Reviews for CGP 39551
There are currently no reviews for this product. Be the first to review CGP 39551 and earn rewards!
Have you used CGP 39551?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.